StockNews.AI
TMO
StockNews.AI
17 days

Thermo Fisher's NGS Assay Receives FDA Approval as a Companion Diagnostic for ZEGFROVY and for Tumor Profiling

1. FDA approves Thermo Fisher's Oncomine Dx Express Test as companion diagnostic. 2. This expands Thermo Fisher's NGS capabilities in decentralized clinical settings.

2m saved
Insight
Article

FAQ

Why Bullish?

FDA approvals typically drive stock values up, similar to prior approvals. For instance, previous diagnostic approvals by TMO have historically spurred positive market responses.

How important is it?

FDA approval enhances TMO's product offering and market position, likely increasing revenue streams. The approval also opens doors for partnerships and further innovations in diagnostics.

Why Short Term?

Immediate market reactions can be expected due to FDA approval news, affecting sales short-term. Historical trends show significant stock activity following major FDA announcements.

Related Companies

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the U.S. Food and Drug Administration (FDA) has approved the Oncomine™ Dx Express Test on the Ion Torrent™ Genexus™ Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay for use as a companion diagnostic (CDx) for Dizal's ZEGFROVY® (sunvozertinib) and in tumor profiling. This approval brings rapid next-generation sequencing (NGS) to decentralized clinical settings closer to.

Related News